We found variants in the WNT signaling pathway were associated with reduced cancer incidence and improved cancer survival compared with variant TP53 carriers lacking variants in the WNT signaling pathway, and even more so compared with those with at least one class 1–3 variant. This evidence concerns the gene TP53 and cancer.